comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 18:49:28 - browse：4

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： MoonLake credibility takes another hit with mid

focus

WSS

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Extreme heat events are a public health emergency

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Bernie Sanders gets little from pharma CEOs on drug prices

10 million people disenrolled from Medicaid over past six months

White House calls on federal agencies to crack down on AI abuses

focus

comprehensive

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Tome Biosciences co

Wildfire smoke exposes gaps in outdoor worker protections

Ambulance rides for just $100? Advisers want major billing fixes

As demand for Covid shots wanes, Moderna seeks its next success

Medicare solvency divides Republicans at the presidential debate

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why Eli Lilly’s earnings didn’t quite live up to the hype

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The Sacklers, horror, and ‘The Fall of the House of Usher’

focus

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Victims of gun violence feel impacts long after bullet wound

Extreme heat events are a public health emergency

Medicare solvency divides Republicans at the presidential debate

HPV cancer vaccine study demonstrates efficacy

AMAs digital advisors table RPM coding reform proposal, again

focus

focus

knowledge

leisure time